These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 16830315)
1. Intravenous flumazenil for Parkinson's disease: a single dose, double blind, placebo controlled, cross-over trial. Ondo WG; Silay YS Mov Disord; 2006 Oct; 21(10):1614-7. PubMed ID: 16830315 [TBL] [Abstract][Full Text] [Related]
2. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Ondo WG; Hunter C Mov Disord; 2003 Jun; 18(6):683-5. PubMed ID: 12784272 [TBL] [Abstract][Full Text] [Related]
3. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Murata M; Hasegawa K; Kanazawa I; Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492 [TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937 [TBL] [Abstract][Full Text] [Related]
5. Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study. Van der Rijt CC; Schalm SW; Meulstee J; Stijnen T Gastroenterol Clin Biol; 1995; 19(6-7):572-80. PubMed ID: 7590022 [TBL] [Abstract][Full Text] [Related]
6. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088 [TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Hauser RA; Lyons KE; McClain T; Carter S; Perlmutter D Mov Disord; 2009 May; 24(7):979-83. PubMed ID: 19230029 [TBL] [Abstract][Full Text] [Related]
8. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. Pahwa R; Koller WC; Trosch RM; Sherry JH; J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338 [TBL] [Abstract][Full Text] [Related]
9. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Simpson DM; Messina J; Xie F; Hale M Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282 [TBL] [Abstract][Full Text] [Related]
10. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Nutt JG; Carter JH; Carlson NE Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373 [TBL] [Abstract][Full Text] [Related]
11. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM; Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243 [TBL] [Abstract][Full Text] [Related]
12. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study. Simon N; Micallef J; Reynier JC; Lesourd M; Witjas T; Alicherif A; Azulay JP; Blin O Mov Disord; 2005 Jul; 20(7):803-9. PubMed ID: 15726579 [TBL] [Abstract][Full Text] [Related]